Trade Novavax

Novavax, Inc. is an American vaccine development company based in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. As of 2020, it had a phase III clinical trial going on in the elderly for a candidate vaccine for seasonal influenza, NanoFlu and filter vaccine (NVX-CoV2373) for the prevention of COVID-19. Novavax was founded in 1987. It focused mainly on the development of the experimental vaccine, but it was never successful until june 2021.In 2013, and Novavax acquired matrix-M adjuvant with the purchase of The Swedish company Isconova AB and renamed its new branch Novavax AB. In 2015, the company received an $89 million grant from the Bill and Melinda Gates Foundation to support the development of a vaccine against the simultaneous human respiratory virus of infants by immunizing mothers. In March 2015, the company completed the trial of its first phase of the Ebola vaccine filter, as well as a phase II study in adults of its anti-retroviral vaccine, which would become ResVax. The ResVax trial was encouraging because it showed great efficacy against RSV.2016 infection that saw the failure of the company's first phase III trial, the 12,000 adult solution trial, for the respiratory sync virus vaccine, known as ResVax, in September. This led to an 85 per cent decline in the company's share price. The results of phase II adult trials also released in 2016 showed antibiotic stimulation, but failure to be effective. An assessment of these findings suggests that an alternative sting strategy may lead to success, leading to plans to manage new trials in the second phase. The difficulties i encountered led The company in 2016 to a three-part strategy for 2017: cutting costs through restructuring and ending 30% of its workforce; pouring more effort into getting ResVax to the market; and starting clinical trials on the Zika virus vaccine. In addition to adult studies in ResVax, the vaccine was also tested in 2016 against RSV infant infection through a maternal immunization pathway. In 2019, clinical tests failed in the late stages of ResVax for the second time, resulting in a significant decline in investor confidence and a 70 per cent drop in the company's capital value. As a by-product, the company was forced to make a reverse split in the shares in order to maintain minimum qualifications on nasdaq, which meant that it was at risk of being delisted. The company positions NanoFlu to meet the unmet needs of a more effective influenza vaccine, especially in older people who often suffer from serious and sometimes life-threatening complications. In January 2020, it was granted fast-track status by the U.S. Food and Drug Administration (FDA) for NanoFlu.